Literature DB >> 23953580

Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models.

X B Meng1, X L Bi, H L Zhao, J B Feng, J P Zhang, G M Song, W Y Sun, Y W Bi.   

Abstract

BACKGROUND: Intimal hyperplasia plays an important role in vein graft stenosis. Inflammatory injury, especially nuclear factor kappaB (NF-κB) gene activation, is highly involved in stenosis progression. We examined whether neointimal hyperplasia and vein graft stenosis could be inhibited by silencing the NF-κB gene with small interference RNA (siRNA).
METHODS: Sixty adult male Sprague-Dawley rats were randomly divided into a normal vein group, a vein graft group, a scrambled siRNA group, and an NF-κB siRNA group. We performed reverse interpositional grafting of the autologous external jugular vein to the abdominal aorta. Vein grafts were treated with liposome and gel complexes containing NF-κB siRNA or scrambled siRNA. The levels of monocyte chemoattractant protein -1, tumor necrosis factor-α, and NF-κB p65 in vessel tissues were evaluated after surgery for content of proliferating cell nuclear antigen (PCNA) and vascular wall thickness.
RESULTS: NF-κB siRNA treated vein graft showed less neointimal formation and fewer positive PCNA cells (P < .05). In addition there were lower levels of, NF-κB p65 protein and of inflammatory mediators (P < .05) compared with the vein graft group.
CONCLUSION: Our study suggested that siRNA transfection suppressed NF-κB expression, reduced inflammatory factors, lessened neointimal proliferation, and suppressed PCNA.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23953580     DOI: 10.1016/j.transproceed.2013.03.045

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

Review 2.  Current siRNA targets in the prevention and treatment of intimal hyperplasia.

Authors:  Leena Pradhan-Nabzdyk; Chenyu Huang; Frank W LoGerfo; Christoph S Nabzdyk
Journal:  Discov Med       Date:  2014-09       Impact factor: 2.970

3.  Upregulation of miR-126-3p promotes human saphenous vein endothelial cell proliferation in vitro and prevents vein graft neointimal formation ex vivo and in vivo.

Authors:  Qingxi Qu; Weidong Bing; Xiangbin Meng; Jie Xi; Xiao Bai; Qing Liu; Yaqiu Guo; Xin Zhao; Yanwen Bi
Journal:  Oncotarget       Date:  2017-11-03

4.  The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.

Authors:  Ben J Wu; Yue Li; Kwok-Leung Ong; Yidan Sun; Douglas Johns; Philip J Barter; Kerry-Anne Rye
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.996

5.  miRNA-126-3p carried by human umbilical cord mesenchymal stem cell enhances endothelial function through exosome-mediated mechanisms in vitro and attenuates vein graft neointimal formation in vivo.

Authors:  Qingxi Qu; Limei Wang; Weidong Bing; Yanwen Bi; Chunmei Zhang; Xuanxuan Jing; Linghong Liu
Journal:  Stem Cell Res Ther       Date:  2020-11-02       Impact factor: 6.832

Review 6.  The Etiology and Molecular Mechanism Underlying Smooth Muscle Phenotype Switching in Intimal Hyperplasia of Vein Graft and the Regulatory Role of microRNAs.

Authors:  Dengshen Zhang; Yiran Cao; Daxing Liu; Jian Zhang; Yingqiang Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-28

Review 7.  Inflammation in Vein Graft Disease.

Authors:  Margreet R de Vries; Paul H A Quax
Journal:  Front Cardiovasc Med       Date:  2018-01-24

8.  Exosomes derived from human umbilical cord mesenchymal stem cells inhibit vein graft intimal hyperplasia and accelerate reendothelialization by enhancing endothelial function.

Authors:  Qingxi Qu; Yingxin Pang; Chunmei Zhang; Linghong Liu; Yanwen Bi
Journal:  Stem Cell Res Ther       Date:  2020-03-23       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.